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Cancer cells frequently depend on chromatin regulatory activities to maintain a malignant phenotype. Here, we
show that leukemia cells require the mammalian SWI/SNF chromatin remodeling complex for their survival and
aberrant self-renewal potential. While Brg1, an ATPase subunit of SWI/SNF, is known to suppress tumor
formation in several cell types, we found that leukemia cells instead rely on Brg1 to support their oncogenic
transcriptional program, which includes Myc as one of its key targets. To account for this context-specific
function, we identify a cluster of lineage-specific enhancers located 1.7 Mb downstream from Myc that are
occupied by SWI/SNF as well as the BET protein Brd4. Brg1 is required at these distal elements to maintain
transcription factor occupancy and for long-range chromatin looping interactions with theMyc promoter. Notably,
these distal Myc enhancers coincide with a region that is focally amplified in ~3% of acute myeloid leukemias.
Together, these findings define a leukemia maintenance function for SWI/SNF that is linked to enhancer-mediated
gene regulation, providing general insights into how cancer cells exploit transcriptional coactivators to maintain
oncogenic gene expression programs.
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Comprehensive profiling of cancer genomes has revealed
that somatic mutation of genes encoding chromatin
regulators is a common driver mechanism of tumorigen-
esis (Garraway and Lander 2013). While the full mecha-
nistic consequences of these mutations remain poorly
understood, one expectation is that such events promote
acquisition of cancer cell capabilities through alteration
of transcriptional programs. Consequently, targeting the
chromatin regulatory machinery provides a means of
extinguishing oncogenic gene expression programs for
therapeutic purposes (Popovic and Licht 2012). In support
of this concept, small-molecule-based inhibition of select
chromatin regulators has shown efficacy in clinical and
preclinical cancer settings (Dawson and Kouzarides 2012).
However, a major ongoing challenge remains in identify-
ing and understanding cancer-specific dependencies on
chromatin regulatory activities.
ATP-dependent nucleosome remodeling enzymes are a
major category of chromatin regulators, of which SWI/
SNF (also known as BAF in mammals) is one of the best
studied (Hargreaves and Crabtree 2011). First discovered
in yeast, SWI/SNF complexes couple ATP hydrolysis to
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the perturbation of histone:DNA contacts to promote
access of transcription factors (TFs) to their cognate DNA
elements (Cote et al. 1994). SWI/SNF complexes lack
intrinsic DNA sequence specificity; hence, they are typi-
cally recruited to genomic sites through physical interac-
tions with sequence-specific TFs (Neely et al. 1999). As
such, SWI/SNF functions as a unique coactivator that
both stabilizes TF occupancy and facilitates downstream
steps in transcriptional activation (Neely et al. 1999).
Mammalian SWI/SNF complexes are comprised of ;11
subunits that are encoded by ;19 distinct genes, thereby
affording diverse combinatorial assemblies with special-
ized functions (Wu et al. 2009). For example, SWI/SNF
contains one of two possible ATPase subunits, Brg1 or Brm,
both of which also possess a bromodomain that interacts
with acetylated histones (Wang et al. 1996). Despite their
similar domain architectures, Brg1 and Brm each inter-
acts with distinct families of TFs to confer unique func-
tional outputs to the complex (Kadam and Emerson 2003).
Tissue-specific expression patterns of certain SWI/SNF
subunits can also lead to tailoring of subunit configura-
tions for lineage-specific functionalities (Olave et al. 2002).
Individual SWI/SNF subunits are known to perform
specialized functions in the hematopoietic system. For
example, conditional inactivation of Smarcb1 (encoding
BAF47) and Actl6a (encoding BAF53a) in mice leads to
severe defects in multilineage hematopoiesis, whereas
a mutant allele of Arid1a (encoding BAF250a) leads to
hematopoietic stem cell expansion through a non-cell-
autonomous mechanism (Roberts et al. 2002; Krosl et al.
2010; Krasteva et al. 2012). Smarca4 (encoding Brg1)
mutant mice display defective erythroid and lymphoid
differentiation, whereas hematopoietic stem cells, com-
mon myeloid progenitors, and mature myeloid popula-
tions are maintained at normal levels (Chi et al. 2003;
Bultman et al. 2005; Willis et al. 2012; S. Bultman, pers.
comm.). SWI/SNF interacts with several hematopoietic
TFs (e.g., Runx1 and EKLF) whose functional impairment
in SWI/SNF-deficient animals may account for these hema-
topoietic abnormalities (Kadam and Emerson 2003; Bakshi
et al. 2010).
Genomic studies have uncovered a pervasive tumor
suppressor role for SWI/SNF complexes, with a frequency
of mutation across human cancer being estimated at
;18%–20% (Kadoch et al. 2013; Shain and Pollack
2013). This includes loss-of-function mutation of genes
encoding BAF250a, Brg1, BAF47, and BAF180, which are
particularly common in ovarian, lung, rhabdoid, and renal
cell cancers, respectively (Kadoch et al. 2013; Shain and
Pollack 2013). In leukemias, decreased SWI/SNF subunit
expression has been associated with glucocorticoid re-
sistance in acute lymphoblastic leukemia (ALL) (Pottier
et al. 2008), and genetic loss of SMARCB1 has been ob-
served in cases of chronic myeloid leukemia (CML)
(Grand et al. 1999). However, the functional involvement
of SWI/SNF in leukemia progression is currently not well
understood. Interestingly, SWI/SNF mutations have not
been found as recurrent alterations in large-scale genomic
studies of acute myeloid leukemia (AML) (The Cancer
Genome Atlas Research Network 2013), raising the
possibility that in this particular cancer, SWI/SNF may
not act as a tumor suppressor.
We show here instead that Brg1-containing SWI/SNF
complexes are critical for the oncogenic transcriptional
program of leukemia cells. This includes a direct role for
Brg1 in the maintenance of Myc expression, which we
link to a cluster of distal enhancer elements at the Myc
locus that are lineage-specific and coincide with a region
known to be focally amplified in AML.At these enhancers,
Brg1 is critical to sustain TF occupancy and enable long-
range looping interactions with the Myc promoter. Col-
lectively, our study implicates a role for SWI/SNF in
maintaining the epigenetic state of leukemia cells.
Results
Brg1 and other SWI/SNF subunits are required
for leukemia cell expansion
We previously performed an shRNA screen that aimed to
identify chromatin regulator dependencies in a mouse
model of MLL-AF9/NrasG12D AML (Zuber et al. 2011c).
Here we investigated the leukemiamaintenance function
of Brg1/Smarca4, which scored as a strong hit in this prior
screen (Zuber et al. 2011c). We first confirmed the anti-
proliferative effects of Brg1 knockdown in leukemia cells
using a competition-based assay. Murine MLL-AF9/
NrasG12D AML cells (RN2 cell line) transduced with
shRNAs targeting Brg1 were rapidly outcompeted by
untransduced cells within 6 d in culture—effects nearly
as strong as a validated shRNA targeting the BET protein
Brd4, which is a known requirement in this model (Fig.
1A; Zuber et al. 2011c). Taking advantage of the Tet-On
competence of the RN2 line, we further examined the
Brg1 requirement for AML progression under in vivo
conditions (Zuber et al. 2011a). Conditional knockdown
of Brg1 in established disease led to significant inhibition
of disease progression, as measured by bioluminescent
imaging of leukemia burden and extension of animal
survival (Fig. 1B,C; Supplemental Fig. 1). These findings
confirm the Brg1 requirement for disease expansion in
a genetically engineered mouse model of MLL-AF9/
NrasG12D AML.
We next evaluated the specificity of proliferation arrest
caused by Brg1 knockdown in various cell backgrounds.
Reducing Brg1 levels in RN2 cells led to G1/G0 arrest and
cell death, whereas an equivalent knockdown in immor-
talized murine embryonic fibroblasts (iMEFs) had no
significant effect on cell cycle progression or cell survival
(Fig. 1D,E; data not shown). We also found that Brg1
shRNAs inhibitedproliferationof cells derived fromamouse
model of B-cell ALL (B-ALL) initiated by the BCR-ABL
oncogene and p19Arf deficiency (Supplemental Fig. 2A;
Williams et al. 2006). This indicates that the Brg1 require-
ment for leukemia proliferation is not restricted to myeloid
leukemia or MLL fusion subtypes of disease. In contrast,
murine melanoma and breast cancer cell lines proliferated
normally despite stable Brg1 knockdown (Supplemental
Fig. 2A,B). These findings indicate that the Brg1 require-
ment for cell proliferation is highly cell context-dependent.
Shi et al.
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Figure 1. Brg1 and other SWI/SNF subunits are required for AML maintenance. (A) Competition assay to measure the effects of
shRNAs on leukemia cell proliferation. The percentage of GFP+/shRNA+ RN2 cells was measured at the indicated time points.
Percentages were normalized to day 2 values. shRen.713 is a negative control shRNA targeting Renilla luciferase. n = 3. (B,C)
Conditional shRNA experiments performed in vivo. Clonal RN2-TRMPV-Neo lines were transplanted into sublethally irradiated
recipient mice followed by administration of doxycycline (dox) at day 6. (B) Bioluminescent imaging of the luciferase+ leukemia burden
at the indicated days following dox administration. (C) Kaplan-Meier survival curves. Nine to 10 mice were included in each shRNA
group. Statistical significance was calculated using a log-rank test. (*) P < 0.001. (D) Cell cycle and Western blot analysis following dox-
induced knockdown of Brg1 in RN2 and iMEF lines transduced with TRMPV-Neo shRNA constructs. shRNAwas induced for 48 h with
dox followed by BrdU incorporation assays and Western blotting of whole-cell lysates. n = 3. Western blot is a representative of three
independent replicates. (E) Measurement of nonviable cells following conditional Brg1 knockdown. shRNA was induced for 72 h with
dox. n = 3. (F) Western blotting of Brg1 levels in whole-cell lysates prepared from HeLa cells transduced with the indicated MLP-shRNA
constructs. A representative experiment of three independent replicates is shown. (G) Competition assay in NOMO-1 cells (human
MLL-AF9+ AML) using the indicated shRNA constructs, as described for A. n = 3. (H) Summary of competition assay data from RN2
cells for 93 independent shRNAs targeting the indicated SWI/SNF subunits. The average fold decrease in GFP percentage over 10 d for
four to six independent shRNAs is plotted. Bars are labeled in red if more than two independent shRNAs decreased the percentage of
GFP+ more than threefold. All error bars represent SEM.
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Using shRNAs that are specific to the human gene, we
next evaluated the Brg1 requirement in different human
leukemia cell lines (Fig. 1F). Proliferation of AML lines
harboring endogenous MLL rearrangements (NOMO-1,
MV4-11, andMOLM-13) was sensitive to Brg1 knockdown,
confirming this subtype of disease as Brg1-dependent (Fig.
1G; Supplemental Fig. 3A). Interestingly, an AML line
carrying the AML1-ETO fusion protein (KASUMI-1) was
also sensitive to Brg1 knockdown, whereas other AML
lines were less affected (HEL and CMK) (Supplemental
Fig. 3A). This suggests that Brg1 is required in multiple
subtypes of AML but is not a universal requirement in
this disease. Proliferation of human T-ALL and B-ALL
lines JURKAT and REH, respectively, and the CML blast
crisis line K-562 was also inhibited upon Brg1 knockdown
(Supplemental Fig. 3A). This overall pattern of sensitivity
was distinct from other strong hits in our prior screen
(Zuber et al. 2011c), such as SPT16, a subunit of the FACT
histone chaperone complex, whose knockdown strongly
inhibited proliferation across all human lines examined
(Supplemental Fig. 3A,B). These findings suggest that
a subset of leukemias require Brg1 to proliferate.
Since Brg1 is a constituent of SWI/SNF, we also evalu-
ated whether other subunits of this complex were required
for leukemia proliferation. We designed four to six in-
dependent shRNAs targeting each SWI/SNF subunit (93
shRNAs in total), which were evaluated one by one in
a competition assay for effects on RN2 cell proliferation.
Notably, BAF60c, BAF45b, BAF45c, and BAF53b are not
expressed in RN2 cells andwere excluded from the screen
(Supplemental Fig. 4A). This shRNA screen identified
BAF60b, BAF53a, BAF250a, BAF60a, BAF155, and BAF45d
as additional requirements for RN2 proliferation based on
a criteria of (1) multiple independent shRNAs reducing
the GFP+ percentage more than threefold over 10 d in the
competition assay and (2) validated on-target knockdown
measured by RT-qPCR for growth inhibitory shRNAs
(Fig. 1H; Supplemental Fig. 4B,C). Collectively, these
results suggest that specific Brg1-containing SWI/SNF
complexes are required for leukemia maintenance.
Brg1 promotes self-renewal of leukemia cells
by maintaining Myc transcription
Since impaired differentiation is a property of AML,
we next considered whether Brg1 regulates the line-
age profile of leukemia cells. Following conditional Brg1
knockdown, RN2 cells transitioned from an immature
blast morphology to one resembling mature macrophages
(Fig. 2A). Consistent with this observation, Brg1 knock-
down also decreased the cell surface levels of the leukemia
stem cell (LSC) marker ckit and increased the levels of
Mac1, a macrophage marker (Fig. 2B, 2C). We further
evaluated the effect on cell differentiation using gene set
enrichment analysis (GSEA) of expression microarray
data obtained from Brg1-deficient leukemia cells follow-
ing conditional knockdown using three independent Brg1
shRNAs (Subramanian et al. 2005). This revealed a sig-
nificant decrease in the expression of genes known to be
enriched in LSCs as well as an increase in the expres-
sion of macrophage-related genes upon Brg1 knock-
down (Fig. 2D,E). Taken together, these findings suggest
that Brg1 is required to preserve an undifferentiated cell
state in AML.
To explain the differentiation phenotype seen in Brg1-
deficient AML cells, we examined the expression of
known regulators of self-renewal in leukemia using the
transcriptome data described above. While expression of
several regulators was perturbed upon Brg1 knockdown,
Myc was among the most down-regulated genes identi-
fied (P < 0.01) (Fig. 3A). Hoxa9, which is a direct target of
the MLL-AF9 oncoprotein, was also down-regulated (P <
0.01), albeit to a lesser extent than Myc (Fig. 3A). Gene
signatures linked to Myc and Hoxa9 function were
globally suppressed following Brg1 knockdown, further
confirming an effect on these two pathways (Fig. 3B,C;
Supplemental Fig. 5). We noted that the majority of direct
MLL-AF9 target genes (Bernt et al. 2011), however, were
not down-regulated upon Brg1 knockdown (data not
shown), suggesting that MLL-AF9 and Brg1 display over-
lapping functions at select genes yet are largely distinct
from one another in their regulatory activities. We found
that Myc expression was also Brg1-dependent in murine
BCR-ABL+ B-ALL, whereasMyc levels were unaffected by
Brg1 knockdown in iMEFs or melanoma or breast cancer
lines. (Fig. 1D; Supplemental Fig. 2B). Thus, the effect on
Myc expression correlates with the Brg1 requirement for
proliferation across these different lines. We found that
Myc expression was also rapidly decreased within the
first 24 h of Brg1 knockdown in RN2 cells, suggesting
direct regulation (Fig. 3E).
Since Brg1 knockdown leads to a differentiation phe-
notype similar to that observed upon Myc inhibition
(Zuber et al. 2011b) and Myc is a potent oncogene in
AML (Luo et al. 2005), we evaluated the functional
significance of Myc to the Brg1 requirement in leukemia
cells. When transcribed from a retroviral promoter, the
expression level ofMycwas significantly less sensitive to
Brg1 knockdown (Fig. 3F), suggesting that Brg1 regulates
Myc primarily from its endogenous chromosomal con-
text. Notably, leukemia cells transduced with retroviral
Myc constructs were resistant to cell cycle arrest and
myeloid differentiation induced by Brg1 knockdown (Fig.
3G,H), indicating that maintenance of endogenous Myc
expression is one key function of Brg1 in this disease.
Myc-transduced RN2 cells still underwent cell death
following Brg1 knockdown (data not shown), indicating
a Myc-independent function of Brg1 in regulating cell
survival. Consistent with this possibility, Brg1 knock-
down globally altered the expression of apoptosis regula-
tors (Fig. 3D), with several proapoptotic genes being
prominently up-regulated following Brg1 knockdown
(e.g., Bid, Btg1, and Bmf; P < 0.01 for each) (Fig. 3A). From
this analysis, we conclude that Brg1 maintains a gene
expression program that supports leukemia cell expan-
sion, which includes Myc as one of its key downstream
targets.
The regulatory functions of Brg1 in RN2 cells are
highly similar to the previously described functions of
the BET protein Brd4, which also promotes Myc tran-
Shi et al.
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scription in this leukemia model (Dawson et al. 2011;
Zuber et al. 2011c). To evaluate the similarity between
Brd4 and Brg1 functions, we first performed a time-
course RNA sequencing (RNA-seq) analysis to define
a group of 53 genes whose expression is rapidly reduced
following exposure to JQ1, a small-molecule inhibitor of
BET bromodomains (Supplemental Fig. 6A; Filippakopoulos
et al. 2010). Using GSEA, we found that nearly all of these
53 genes were also suppressed following Brg1 knockdown
(Supplemental Fig. 6B), suggesting that Brg1 and Brd4
regulate a highly overlapping set of genes in RN2 cells,
which includes Myc. Prior proteomic studies found an
association between SWI/SNF subunits and BET proteins
(Denis et al. 2006; Dawson et al. 2011; Rahman et al.
2011), which we also have confirmed and found to be
mediated by the ET domain of Brd4 (Supplemental Fig.
6C–E). However, using ChIP-qPCR, we found that Brg1
and Brd4 occupy chromatin independently of one another
at all of the sites we examined (Supplemental Fig. 6F,G),
suggesting that, despite their apparent physical associa-
tion, Brg1 and Brd4 operate in parallel pathways tomaintain
a common gene regulatory network in this disease. The
similar regulatory functions of Brg1 and Brd4 in leukemia
might be related to both factors regulating gene expres-
sion through common cis elements, as described below.
Brg1 occupies a cluster of lineage-specific enhancers
(E1–E5) located 1.7 Mb downstream from Myc
An important question raised by our findings is how Brg1
can promoteMyc expression specifically in leukemia but
not in other cell types, since both Brg1 and Myc are
Figure 2. Brg1 maintains an undifferentiated cell state in AML. (A) Light microscopy of May-Grunwald/Giemsa-stained RN2 cells
transduced with the indicated TRMPV-Neo shRNA constructs. Cells were treated with dox for 3 d. Imaging was performed with
a 403 objective. A representative image of three independent biological replicates is shown. (B,C) Flow cytometry analysis of c-kit
(B) and Mac-1 (C) surface expression after 96 h of dox treatment. A representative experiment of three biological replicates is
shown. (D,E) GSEA of LSC and macrophage development gene sets following Brg1 knockdown. Microarray analysis was performed
comparing three independent Ren.713 shRNA RN2 lines with three independent Brg1 shRNA RN2 lines (4935, 3364, and 3232).
The dox-inducible TRMPV-Neo vector was used. Dox treatment was for 96 h. (NES) Normalized enrichment score; (FDR),false
discovery rate.
SWI/SNF in leukemia maintenance
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expressed ubiquitously. To explain this observation, we
hypothesized that Brg1 regulates Myc transcription in
leukemia cells by occupying cell type-specific regulatory
elements. We evaluated this possibility by performing
chromatin immunoprecipitation (ChIP) followed by next-
generation sequencing (ChIP-seq) analysis of Brg1, his-
tone H3 Lys 4 trimethylation (H3K4me3), and histone
H3 Lys 27 acetylation (H3K27ac) in RN2 leukemia cells
Figure 3. Brg1 maintains Myc and Hoxa9 expression and represses proapoptotic genes in AML. (A) Heat map of gene expression
changes following Brg1 knockdown using microarray data described above. Each protein-coding gene represented on the array is ranked
based on fold change in expression, with the position of select genes indicated by horizontal lines. Results are the average of three
independent Brg1 shRNAs. (B–D) GSEA following Brg1 knockdown, as described in Figure 2. (E) Time-course Western blotting of Myc
and Brg1 levels in RN2 cells following dox treatment of TRMPV-Neo RN2 lines with the indicated shRNAs. shRNA expression was
triggered by dox for the indicated amount of time before lysate preparation. (F) Western blotting following 48 h of dox-induced Brg1
knockdown performed in AML (RN2) cells that were pretransduced with either MSCV-em (empty) or MSCV-Myc vectors. A
representative experiment of three biological replicates is shown. (G) BrdU cell cycle analysis performed on day 3 of dox treatment.
n = 3. (H) Imaging of cell morphology of the same cells as described in F. All error bars represent SEM.
Shi et al.
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(Fig. 4A). We also included Brd4, a known regulator ofMyc
transcription in leukemia cells, in this analysis, since its
role at distal regulatory elements was not evaluated in
prior studies (Dawson et al. 2011;Mertz et al. 2011; Zuber
et al. 2011c). A survey of the extendedMyc locus revealed
Brg1 and Brd4 occupancy in the vicinity of the Myc
promoter and at a prominent cluster of peaks located
1.7 Mb downstream (Fig. 4A). We refer to this cluster of
distal elements here as E1–E5 (Fig. 4B). E1–E5 all displayed
enrichment for H3K27ac and only low levels of H3K4me3,
suggesting that this region may contain active enhancers
(Fig. 4A,B; Rada-Iglesias et al. 2011). The strong enrich-
ment of Brd4 occupancy at these sites classifies these
elements as a ‘‘super-enhancer,’’ using the criteria of
Figure 4. Intergenic occupancy of Brg1 and Brd4 1.7 Mb downstream fromMyc coincides with a region of recurrent focal amplification
in AML. (A) ChIP-seq occupancy profiles of Brg1, Brd4, H3K27ac, and H3K4me3 obtained in RN2 cells (in reads per million). Myc is
transcribed from left to right in this depiction. Validated transcript models from the mm8 genome assembly are depicted below. (*)
Noncoding RNAs. (B) ChIP-seq data in a window of ;130 kb surrounding the E1–E5 regions. (C) The locations of somatic copy number
amplifications identified on human chromosome 8 from prior studies are represented as solid red lines (Radtke et al. 2009; Kuhn et al.
2012). The labels indicate sample IDs used in the prior studies. Locations are depicted on the hg19 genome assembly.
SWI/SNF in leukemia maintenance
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Loven et al. (2013) (Supplemental Fig. 7). Interestingly,
the E1–E5 region is closely matched to a previously re-
ported location of recurrent focal amplification seen pre-
viously in;3% of AML cases (Fig. 4C; Radtke et al. 2009;
Kuhn et al. 2012). We observed a trend that The Cancer
Genome Atlas (TCGA) tumor samples harboring geno-
mic amplifications 39 ofMYC (not containingMYC itself)
tended to have higher MYC mRNA levels (Supplemental
Fig. 8). These findings together raised the possibility that
E1–E5 are distal enhancer elements that control Myc
expression in leukemia cells.
We first examined whether Brg1 occupancy at E1–E5
was lineage-specific and hence could be correlated with
the Brg1 requirement for Myc expression. While Brg1
occupied the Myc promoter region in all of the cell types
examined, Brg1 occupancy at E1–E5 was found only in
leukemia cell lines (RN2, B-ALL, and NOMO-1) (Fig.
5A–E; Supplemental Fig. 9). Indeed, an evaluation of
published ChIP-seq data obtained from normal mouse
tissues revealed that despite ubiquitous acetylation near
the Myc promoter, H3K27ac was absent from the E1–E5
region in most normal mouse tissues (Fig. 5F; Supple-
mental Fig. 10A; Shen et al. 2012). We detected low-level
yet significant H3K27ac enrichment at the E1–E5 ele-
ments in normal bonemarrow, embryonic day 14.5 (E14.5)
fetal livers (which are largely hematopoietic), and mature
myeloid cells (bone marrow-derived macrophages), sug-
gesting that E1–E5 is also active in normal hematopoietic
cells (Fig. 5F; Supplemental Fig. 10B). Luciferase reporter
assays linked to a minimal thymidine kinase promoter
revealed that E3 exhibits enhancer activity in K-562
leukemia cells but not in a nonleukemia cell line,
HEK293T (Fig. 5G). K-562 was used for this experiment
because it was the only leukemia line that we could
readily transfect with reporter constructs. K-562 harbors
H3K27ac and Brg1 enrichment at its endogenous E3
region but not at E1–E2 or E4–E5 (Supplemental Fig. 11).
Notably, we detected occupancy of BAF250a and BAF60a
at the E1–E5 regions in RN2 cells, suggesting the presence
of a SWI/SNF complex at these sites (Supplemental Fig.
12). These findings together suggest that E1–E5 elements
are a cluster of lineage-specific enhancers that are occu-
pied by Brg1-containing SWI/SNF complexes.
Based on the findings described above, we reasoned that
enhancer activity at E1–E5 was likely to reflect occu-
pancy of hematopoietic TFs, whose expression and/or
function might be deregulated in leukemia cells. By
analyzing ChIP-seq data of TF occupancy obtained pre-
viously from immortalized HPC-7 hematopoietic stem
and progenitor cells (Wilson et al. 2010), we found that
seven hematopoietic TFs occupied various combinations
of the E1–E5 elements (Erg, Fli1, Gfi1b, Lmo2, Meis1,
Pu.1, and Runx1) (Fig. 5H). Since all of these TFs are
expressed in RN2 cells (Supplemental Fig. 13), we antic-
ipated that these factors would occupy E1–E5 in leukemia
as well. Indeed, we detected occupancy of Lmo2, PU.1,
and Erg at various subsets of the E1–E5 enhancers in RN2
using ChIP-qPCR (Fig. 5I–K). Additionally, we found that
the hematopoietic TFs Cebpa and Cebpb, both of which
are highly expressed in RN2 cells, also occupied the
E1–E5 elements (Fig. 5L,M; Supplemental Fig. 13). Nota-
bly, Runx1, Cebpa, and Cebpb have been shown pre-
viously to associate with SWI/SNF (Kowenz-Leutz and
Leutz 1999; Pedersen et al. 2001; Bakshi et al. 2010).
Furthermore, we found that Flag-tagged PU.1 could immu-
noprecipitate Brg1 with an efficiency comparable with that
of Cebpa (Supplemental Fig. 14), suggesting that multiple
TFs at E1–E5 have the capacity to interact with SWI/SNF.
These data show that the E1–E5 enhancers are occupied by
a set of hematopoietic TFs, of which several have known
roles in promoting leukemogenesis (Rosenbauer and Tenen
2007).
We also found sites of Brg1 occupancy in the vicinity
of Hoxa9 and at the promoters of Bid, Btg1, and Bmf,
suggesting direct regulatory effects at these genes (Sup-
plemental Fig. 15). The presence of Brg1 at the promoters
of Bid, Btg1, and Bmf suggests that Brg1 could suppress
cell death in leukemia cells through direct transcriptional
repression of proapoptotic genes, which is consistent with
prior reports that SWI/SNF can repress transcription of
specific target genes (e.g., Cd4 in thymocyte progenitors)
(Chi et al. 2002). Thus, the direct regulatory effects of Brg1
at multiple genes are likely to account for the entirety of
the Brg1 requirement in this disease.
The Myc locus exists in a lineage-specific conformation
that juxtaposes the E1–E5 enhancers with the Myc
promoter
The E1–E5 enhancers are located nearly 1.7 Mb away
from Myc and are actually closer in genomic distance to
other flanking genes (Gsdmc, Fam49b, and Asap1) (Fig.
6A). While Gsdmc is not expressed in leukemia cells,
Fam49b and Asap1 are expressed but in a manner that is
insensitive to Brg1 knockdown (data not shown). In order
to establish the regulatory target genes of E1–E5, we
performed circular chromosome conformation capture
(4C) coupled with high-throughput sequencing (4C-seq)
in RN2 cells (Splinter et al. 2012; van de Werken et al.
2012). Using an anchor point fixed near E3, 4C-seq analysis
revealed that this enhancer region made preferential
contact withMyc as well as several intervening regions
(Fig. 6A, top). Strikingly, E3 effectively ignored the nearby
Gsdmc, Fam49b, and Asap1 genes, highlighting a selec-
tive looping interaction withMyc that occurs over a sub-
stantial genomic interval (Fig. 6A, top). The directionality
of looping interactions may reflect a spatial constraint
imposed by a topological domain whose boundary lies
between E1–E5 and the nearby genes (Supplemental Fig.
16; Dixon et al. 2012). We also performed 4C-seq analysis
using an anchor point fixed near Myc, which confirmed
its preferential association with E1–E5 and only minimal
associations with upstream sequences (Fig. 6A, bottom).
The E1–E5 enhancers and Myc also make contact with
several intervening noncoding regions; however, the low
levels of histone acetylation and TF occupancy at these
sites suggest that these interactions do not reflect func-
tional enhancer–promoter loops but may instead repre-
sent an additional level of higher-order chromatin struc-
ture (Supplemental Fig. 17). Chromosome conformation
Shi et al.
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Figure 5. E1–E5 elements are a lineage-specific cluster of enhancers occupied by Brg1. (A–E) ChIP-qPCR with Brg1 or control IgG
antibodies. PCR primer amplicons are indicated along the X-axis. Neg refers to a negative control region in a gene desert region, and
2 kb is relative to the Myc transcription start site. n = 3. A–C represent murine cell lines and primer pairs. D and E represent human
lines and primer pairs. (F) ChIP-seq profiles of H3K27ac from the indicated normal mouse tissues, obtained from Shen et al. (2012). The
AML H3K27ac data were obtained from RN2 cells. (BM) Bone marrow; (BMDM) BM-derived macrophages; (SmInt) small intestine. (G)
Enhancer reporter assay. The indicated PGL4.23 constructs were transfected into HEK293T or K562 cells for 48 h followed by
measurement of luciferase activity. Results were normalized to the empty vector control. n = 3. (H) ChIP-seq profiles of TF occupancy
performed in HPC-7 cells, obtained from Wilson et al. (2010). (I–M) ChIP-qPCR with the indicated TFs or control IgG antibodies
performed in RN2 cells. PCR primer amplicons are indicated along the X-axis. Neg refers to a negative control region in a gene desert
region. n = 3. All error bars represent SEM.
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capture (3C) analysis quantified by qPCR also validated
an association between MYC and all five enhancers in
NOMO-1 cells, whereas in HEK293T, these interactions
were undetectable (Fig. 6B). Based on these observations,
we conclude that theMyc locus exists in cell type-specific
chromatin conformations, which, in leukemia cells,
favors contact between the E1–E5 enhancers and the
Myc promoter.
Brg1 facilitates TF occupancy and enhancer–promoter
interactions at the Myc locus
Based on the findings described above, we hypothesized
that Brg1 regulatesMyc transcription in leukemia cells at
least in part through its localization at E1–E5. If this is the
case, then Brg1 knockdown should influence enhancer–
promoter contact and/or the association of other regula-
tory factors at E1–E5. Using 3C-qPCR in NOMO-1 cells,
we observed decreased contact between the E3–E5 en-
hancers and MYC upon Brg1 knockdown, whereas con-
tact between other adjacent fragments andMYCwas less
affected (Fig. 7A). To ascertain whether Brg1 knockdown
influenced global interactions across the Myc locus,
we also performed 4C-seq in Brg1-deficient RN2 cells
(Supplemental Fig. 18). This analysis confirmed that Brg1
knockdown led to decreased interactions between Myc
and E3–E5 as well as reduced contact between Myc and
several other intervening regions (Supplemental Fig. 18).
Interestingly, upon Brg1 knockdown, Myc exhibited in-
creased contact with various upstream DNA elements,
suggesting that Brg1 is required to not only promote
interactions between E3–E5 and Myc but also prevent
inappropriate interactions between Myc and upstream
elements (Supplemental Fig. 18). Thus, Brg1 is an impor-
tant factor in leukemia cells for maintaining the fidelity
of enhancer–promoter interactions at the Myc locus.
To further define the role of Brg1 at the E1–E5 enhancers,
we performed ChIP-qPCR analysis of various enhancer
components in Brg1-deficient leukemia cells. Condi-
tional knockdown of Brg1 did not grossly perturb levels
of H3K4me1 and H3K27ac at E1–E5, suggesting that
enhancer-associated histone modifications were main-
tained independently of Brg1 (Fig. 7B–D). In contrast, we
found that Brg1 knockdown led to marked reductions in
the occupancy of several TFs at E1–E5, which included
Cebpa, Cebpb, PU.1, Lmo2, and Erg (Fig. 7E–I). The ex-
pression level of these TFs was largely unaffected by Brg1
knockdown, suggesting a direct effect of Brg1 on TF
Figure 6. E1–E5 enhancers make contact withMyc in leukemia cells. (A) 4C-seq analysis with the indicated anchor points. The Y-axis
measures the normalized contact intensities, which plot the relative proximity of various DNA fragments in this region to the anchor-
point fragment within the three-dimensional nuclear space. E1–E5 enhancers are at the location indicated. A representative experiment
of two independent biological replicates is shown. (B) 3C-qPCR analysis of the interaction frequency of the indicated restriction
fragments with an anchor point fixed near the MYC gene. All PCR signals were normalized to digested/religated bacterial artificial
chromosome (BAC) templates. The gray boxes highlight the regions containing the E1–E5 enhancer elements. n = 3–5. Error bars
represent SEM.
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Figure 7. Brg1 is required for enhancer–promoter proximity and occupancy of hematopoietic TFs at E1–E5. (A) 3C-qPCR analysis of
the interaction frequency of the indicated restriction fragments with an anchor point fixed at the MYC gene. All PCR signals were
normalized to digested/religated BAC templates. The green boxes highlight the regions containing the E1–E5 elements. The experiment
was performed in NOMO-1 following 7 d of dox treatment to induce shRNA expression. n = 3–4. (B–I) ChIP-qPCR analysis performed
in RN2 cells following conditional Brg1 knockdown. RN2 clones transduced with TRMPV-Neo Brg1 shRNA constructs were treated
with dox for 48 h. PCR primer amplicons are indicated along the X-axis. Neg refers to a negative control region found at a gene desert
region. n = 3. (J) The effect of retroviral overexpression of Brg1 mutants (dominant negatives) on RN2 cell proliferation. Wild-type or
mutant Brg1 cDNAs were expressed from an MSCV-IRES-GFP vector. The relative change in GFP percentage over time was used to
infer relative proliferation rates. n = 2–3. All error bars represent SEM.
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occupancy at these sites (Supplemental Fig. 19). We also
detected low levels of RNA produced near E3, whose
production was also inhibited upon Brg1 knockdown
(Supplemental Fig. 20). Collectively, these results suggest
that Brg1 supports TF occupancy, chromatin looping
interactions, and the level of noncoding RNA transcrip-
tion at the E1–E5 enhancers.
The ATPase activity of Brg1 is known to facilitate TF
access to DNA by disrupting nucleosome structure (Cote
et al. 1994). Since Brg1 knockdown influences TF occu-
pancy at E1–E5, we evaluated the relevance of the Brg1
ATPase activity for leukemia cell proliferation. For this
purpose, we employed a dominant-negative approach. We
retrovirally transduced leukemia cells with wild-type or
various Brg1 mutant-expressing constructs and evaluated
their impact on leukemia proliferation (Fig. 7J). While
RN2 cells transduced with wild-type Brg1 proliferated
normally, an ATPase-defective mutant of Brg1 (K798R)
inhibited cell proliferation (Fig. 7J; Khavari et al. 1993). In
contrast, the N1506A mutation in the bromodomain
pocket of Brg1, which is known to diminish acetyl-
histone recognition (Shen et al. 2007), led to minimal
effects on proliferation (Fig. 7J). These results suggest that
the ATPase activity of Brg1 is required for its leukemia
maintenance function.
Discussion
Our study leads to several major conclusions. First, Brg1
and its associated SWI/SNF complex are critical for the
proliferation and viability of leukemia cells, a function
distinct from its tumor suppressor role described pre-
viously in other cancers (Wilson and Roberts 2011). We
relate this observation at least in part to a unique role for
Brg1 in the maintenance of Myc expression in leukemia
cells. To explain this context-dependent regulation, we
identified a cluster of lineage-specific enhancers at the
Myc locus that loop over a 1.7-Mb distance to contact the
Myc promoter. Notably, these lineage-specific enhancers
closely align with a region found previously as a site of
recurrent focal amplification in AML. At these en-
hancers, Brg1 is essential to maintain TF occupancy
and allow long-range communication with the Myc pro-
moter. Additionally, the ATPase activity of Brg1 is critical
for its leukemia maintenance function, presumably by
remodeling nucleosome structure to facilitate TF access.
Our study implicates SWI/SNF as a novel dependency
relevant to multiple subtypes of leukemia, which is linked
to a role for this complex in facilitating enhancer-mediated
regulation of Myc. SWI/SNF is also likely to play addi-
tional roles in leukemia maintenance through repression
of proapoptotic genes and activation of Hoxa9 expression.
A key insight from this study is thatMyc, despite being
broadly expressed in most proliferating cell types, is con-
trolled by highly cell type-specific enhancers, as suggested
through comparisons of H3K27ac profiles across different
tissues (Supplemental Figs. 10, 16). From this perspective,
it would be worthwhile to evaluate whether themultitude
of known regulators of Myc transcription (e.g., FBP1 and
TCF/LEF) also employ tissue-specific enhancers to opti-
mize Myc expression for lineage-specific purposes. When
compared with most other cell lineages, leukemia cells
exhibit a highly unusual enhancer configuration at their
Myc locus, with the most prominent enhancers being
clustered at the extreme boundary of the topological
domain and hence at the maximal distance away from
Myc. Indeed, most other cell types (such as MEFs) exhibit
diffuse localization of nearby enhancers both upstream of
and downstream from Myc (Supplemental Fig. 16). It is
interesting to note that in leukemia cells, Myc transcrip-
tion is highly sensitive to targeting general coactivator
proteins that occupy the E1–E5 enhancers, such as Brg1
and the BET protein Brd4. We speculate that the unique
regulatory configuration at the Myc locus seen in acute
leukemia cells might place an elevated demand on
activator/coactivator machineries for productive expres-
sion. Importantly, the enhancers that we identify here at
the wild-type MYC locus are distinct from IgH trans-
locations involving MYC that have been seen previously
in multiple myeloma, which may likewise impose a
requirement for BET proteins to sustain expression
(Delmore et al. 2011). Remarkably, in both situations
(IgH enhancers in myeloma and E1–E5 enhancers in leuke-
mia), Brd4 occupancy exists at extremely high levels,
a feature recently defined as a ‘‘superenhancer’’ (Loven
et al. 2013). Hence, our findings reinforce the concept that
enhancer-mediated regulation is the functionally relevant
mechanism for cell type-specific control of MYC expres-
sion, with specific enhancer arrangements being differen-
tially sensitive to the targeting of general coactivators.
How might the E1–E5 enhancers become activated in
leukemia cells? The assortment of hematopoietic TFs
(e.g., Fli1, ERG, and Meis1) that occupy E1–E5 raises
several possibilities for how these enhancers are regu-
lated during normal and malignant hematopoiesis. Im-
portantly, the presence of low-level enrichment of H3K27ac
at E1–E5 in unfractionated bone marrow suggests that
E1–E5 is activated in a subpopulation of normal hemato-
poietic cells. Nonetheless, the genes encoding Meis1 and
its binding partner, Hoxa9, are also direct transcriptional
targets of MLL-AF9, suggesting that oncoproteins might
indirectly drive E1–E5 hyperactivation by elevating the
levels of its constituent TFs. Other TFs that occupy E1–
E5 (e.g., ERG) are also known to be overexpressed in AML
(Marcucci et al. 2005), which might lead to E1–E5 hyper-
activation in other leukemia subtypes. We speculate that
elevating the TF content of E1–E5 (and presumably other
enhancers) during leukemogenesis could increase the
demand for SWI/SNF activity to maintain DNA accessi-
bility at these elements, thereby rendering leukemia cells
addicted to SWI/SNF activity for disease maintenance
and progression.
An important observation in this study is that pre-
viously described focal amplifications at 8q24.21 closely
match the position of the E1–E5 Myc enhancers (Radtke
et al. 2009; Kuhn et al. 2012). These amplifications are
highly focal (80–500 kb), with most lacking any protein-
coding genes. The 8q24.21 focal amplifications also over-
lap with a previously described noncoding transcript
called CCDC26, which may possess oncogenic activity
Shi et al.
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(Yin et al. 2006). However, we note that only one of the
nine focal amplifications seen in this AML cohort would
be expected to contain the full-lengthCCDC26 transcript
(Supplemental Fig. 21), and this RNA does not appear to
be conserved in mouse cells (Radtke et al. 2009; Kuhn
et al. 2012; data not shown). While several mechanistic
possibilities exist for how amplifications at 8q24.21 pro-
mote leukemia, our observations raise the possibility that
such events expand the enhancer repertoire at the Myc
locus, which would drive elevated Myc expression to
promote leukemogenesis. Genome editing of E1–E5 du-
plications/deletions will be required to prove such amodel
of leukemogenesis and to definitively establish whether
Brg1 and Brd4 regulate Myc exclusively through an en-
hancer mechanism. A knockout of E1–E5 would also
clarify whether these enhancers have essential functions
during normal hematopoiesis.
Our dominant-negative experiments suggest that tar-
geting the ATPase activity of Brg1, rather than its bromo-
domain, would be the preferred route to elicit anti-leukemia
effects pharmacologically. The ATPase activity of Brg1 is
likely required in leukemia cells to sustain TF occupancy
at critical enhancers that regulate proto-oncogene expres-
sion. While SWI/SNF-deficient mice exhibit a number of
phenotypic defects, recent evidence suggests that dual
inactivation of Brg1 and Brm leads to only minimal
effects on hematopoietic stem and progenitor cells (Willis
et al. 2012), suggesting that there may exist a therapeutic
window for targeting Brg1 in leukemia. Tumors that are
initiated by inactivating mutations of the gene encoding
BAF47 are also hypersensitive to Brg1 inhibition, suggest-
ing additional nonleukemia cancer contexts where tar-
geting Brg1 might have therapeutic utility (Wang et al.
2009). Notably, somatic mutations that inactivate the
ATPase activity of Brg1 are seen in a variety of cancers
(Dykhuizen et al. 2013), highlighting a tumor-protective
function for the nucleosome remodeling activity of Brg1
in certain tissues. Therefore, systemic ATPase inhibition
of Brg1 would be expected to have both pro- and anti-
tumorigenic effects, which would require critical evalu-
ation in preclinical models for the overall safety of such
a therapeutic strategy. Nonetheless, given the diversity of
SWI/SNF complex assemblies known to exist, it may be
possible to avoid the tumorigenic effects of Brg1 inhibi-
tion by instead targeting specific SWI/SNF subunits that
have cancer maintenance functions while preserving sub-
unit functionalities that are linked with tumor protection.
Materials and methods
shRNA/GFP growth competition assay
Cultures were retrovirally transduced with LMN-shRNA
vectors followed by measurement of the GFP percentage
at various days post-infection using a Guava Easycyte
(Millipore). The rate at which the GFP percentage declines
over timewas used to infer the relative growth disadvantage
conferred by a given shRNA relative to the uninfected cells
in the same culture. For human AML cell line experiments,
we used the MLS-shRNA vector, which allows a higher
retroviral transduction efficiency in these lines. Due to
decreased proliferation rates of human AML lines, we
also extended the time of GFP measurements to 28 d.
ChIP-seq
Protocols for performing ChIP have been previously de-
scribed (Boyer et al. 2006). In brief, cells were cross-linked
using 1% formaldehyde for 20 min at room temperature.
Cells were resuspended, lysed in lysis buffers, and soni-
cated with a Misonix Sonicator 3000 to solubilize and
shear cross-linked DNA. The resulting cell extract was
incubated overnight at 4°C with 100 mL of Dynal Protein
G magnetic beads that had been preincubated with
;10 mg of the appropriate antibody. Beads were washed
followed by elution from the beads (50 mM Tris-HCl at
pH 8.0, 10 mM EDTA, 1% SDS) and heating for 1 h at
65°C with vortexing. Cross-linking was reversed by over-
night incubation at 65°C. Following purification of im-
munoprecipitation DNA, Illumina libraries were pre-
pared essentially as described (http://www.illumina.
com/pages.ilmn?ID=203). All ChIP-seq data sets were
aligned using Bowtie (version 0.12.2) to build version
mm8 of the murine genome. All ChIP-SEQ experiments
were performed with two biological replicates, which gave
similar results. All sequencing data have been deposited to
the Gene Expression Omnibus as SuperSeries GSE52279.
ChIP-qPCR
ChIP-qPCR assays were performed exactly as described
(Steger et al. 2008). All results were quantified by qPCR
performed using SYBR Green (Applied Biosystems, Inc.)
on an ABI 7900HT. Each immunoprecipitation signal was
referenced to an input standard curve dilution series
(immunoprecipitation/input) to normalize for differences
in starting cell number and for primer amplification
efficiency.
4C-seq
Preparation of 4C templates was performed as previously
described (Splinter et al. 2012). Experimental details are
provided in the Supplemental Material.
3C
The 3C assay was performed essentially as described (Jing
et al. 2008). Experimental details are provided in the
Supplemental Material.
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